Conversion therapy of intermediate and advanced hepatocellular carcinoma using superstable homogeneous iodinated formulation technology
Crossref DOI link: https://doi.org/10.1007/s11427-022-2142-3
Published Online: 2022-08-26
Published Print: 2022-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Li, Zhenjie
Cheng, Hongwei
Mao, Jingsong
Liu, Gang
Text and Data Mining valid from 2022-08-26
Version of Record valid from 2022-08-26
Article History
Received: 1 April 2022
Accepted: 1 June 2022
First Online: 26 August 2022
Ethics
: <b>Compliance and ethics</b> The author(s) declare that they have no conflict of interest.